News | August 03, 2024
Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The company is planning to expand its plant capacity in in Vapi
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Subscribe To Our Newsletter & Stay Updated
